Irritable Bowel Syndrome (IBS)

01Pathophysiology

Irritable bowel syndrome is a disorder of gut-brain interaction, formerly classified as a functional gastrointestinal disorder. The hallmark is the absence of any identifiable structural, inflammatory, or biochemical abnormality that explains the symptoms. Instead, the disease arises from a dysregulated communication loop between the central nervous system and the enteric nervous system.

The primary mechanism is visceral hypersensitivity, meaning the gut's afferent sensory neurons have a lowered threshold for pain perception. Normal physiologic events such as luminal distension from gas or stool are interpreted centrally as painful. This is why patients report abdominal pain that is disproportionate to any objective finding. On examination, you find nothing, but the patient's suffering is real and reproducible.

Alongside visceral hypersensitivity, there is altered GI motility. In diarrhea-predominant IBS, accelerated colonic transit leads to loose, frequent stools. In constipation-predominant IBS, slowed transit results in hard, infrequent stools. In mixed-type IBS, the motility pattern fluctuates. This directly explains why the bowel habit changes track with the pain episodes.

A third contributor is dysregulated central pain modulation. The descending inhibitory pathways from the brain that normally dampen visceral pain signals are impaired. This explains the strong overlap between IBS and psychiatric conditions like generalized anxiety, depression, and somatization disorder. It also explains why antidepressants, which modulate central pain processing, are effective even in patients without overt depression.

In a subset of patients, IBS develops after an acute bout of infectious gastroenteritis. This is called post-infectious IBS and is thought to result from low-grade mucosal inflammation, persistent immune activation, and changes in the gut microbiome that sensitize enteric neurons. It is the one form of IBS where you can point to a clear precipitating event.

Serotonin (5-HT) plays a key role as a neurotransmitter in the gut. Approximately 95% of the body's serotonin is found in the GI tract, where it regulates motility, secretion, and visceral sensation. Abnormal serotonin signaling is the pharmacologic basis for agents like alosetron (5-HT3 antagonist, slows motility) and tegaserod (5-HT4 agonist, accelerates motility).

02Classification and Clinical Manifestation

IBS is subtyped based on the predominant stool pattern using the Bristol Stool Form Scale. The classification determines the treatment approach, so recognizing the subtype from a vignette is essential.

The Rome IV criteria define IBS as recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: (1) related to defecation, (2) associated with a change in stool frequency, (3) associated with a change in stool form. Symptoms must have started at least 6 months before diagnosis.

Key clinical features across all subtypes include:

03Diagnostic Workup

IBS is fundamentally a clinical diagnosis. The best initial step is to apply the Rome IV criteria at the bedside. If the history fits and there are no alarm features, you can make the diagnosis with confidence and begin treatment. Routine colonoscopy is not required in a young patient who meets Rome IV criteria and has no red flags.

The critical concept here is the alarm features that mandate further investigation. These include: onset after age 50, unintentional weight loss, rectal bleeding or hematochezia, nocturnal diarrhea that wakes the patient, progressive worsening of symptoms, family history of colorectal cancer, inflammatory bowel disease, or celiac disease, iron deficiency anemia, and palpable abdominal mass. If any of these are present in the vignette, the answer is not IBS; it is further workup.

Fecal calprotectin deserves emphasis. It is a neutrophil-derived protein released into the stool during intestinal inflammation. A normal level reliably distinguishes IBS (functional) from inflammatory bowel disease (organic). It is increasingly used as the best initial test to avoid unnecessary colonoscopy in young patients with diarrhea. An elevated fecal calprotectin would redirect you toward colonoscopy and biopsy.

Celiac serologies (tissue transglutaminase IgA) should be checked in all patients with diarrhea-predominant symptoms because celiac disease can mimic IBS exactly. Missing this is a common exam trap.

There is no single confirmatory "gold standard" test for IBS. The diagnosis rests on symptom-based criteria plus the exclusion of organic disease through targeted testing. Colonoscopy is neither the best initial test nor required for diagnosis unless alarm features are present.

04Management and Treatment

The cornerstone of management begins with patient education and reassurance. Explaining that IBS is a real, recognized disorder without life-threatening consequences improves outcomes significantly. This is a testable concept: the next best step in a newly diagnosed IBS patient with no alarm features is reassurance and dietary counseling, not pharmacotherapy.

Dietary modification is the first therapeutic intervention. The low-FODMAP diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) eliminates short-chain carbohydrates that are poorly absorbed and osmotically active, leading to gas, bloating, and altered motility. It is implemented as a strict elimination phase for 4 to 6 weeks, followed by structured reintroduction. Soluble fiber (psyllium) benefits IBS-C but insoluble fiber (wheat bran) can worsen symptoms and should be avoided.

For pain, antispasmodics (dicyclomine, hyoscyamine) are reasonable first-line agents. They reduce smooth muscle contraction in the colon. For refractory pain, tricyclic antidepressants at low doses are the preferred next step. The mechanism is dual: they modulate central pain processing via descending inhibitory pathways and they slow GI transit via anticholinergic effects, which is especially helpful in IBS-D. Start at 10 to 25 mg of amitriptyline at bedtime and titrate slowly. The analgesic effect is independent of the antidepressant effect and occurs at lower doses.

For IBS-D, loperamide controls diarrhea by slowing intestinal transit and reducing stool frequency. It does not improve pain or bloating. Rifaximin, a non-absorbable antibiotic, is used for IBS-D and is particularly effective for bloating. The standard course is 550 mg three times daily for 14 days, and retreatment is allowed for symptom recurrence. Alosetron, a 5-HT3 receptor antagonist, is reserved for women with severe IBS-D who have failed all other therapies. It is available only through a restricted prescribing program because of the risk of ischemic colitis and severe constipation. Eluxadoline, a mixed opioid receptor modulator, is contraindicated in patients without a gallbladder and in those with a history of pancreatitis, biliary obstruction, or heavy alcohol use.

For IBS-C, if fiber and osmotic laxatives fail, linaclotide is the preferred next step. It is a guanylate cyclase-C agonist that increases intestinal chloride and water secretion and reduces visceral pain signaling. It must be taken on an empty stomach 30 minutes before the first meal of the day. Lubiprostone, a chloride channel activator, is an alternative and should be taken with food to reduce nausea. Tegaserod, a 5-HT4 agonist, is restricted to women under 65 with no cardiovascular risk factors due to prior concerns about cardiac events.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on IBS questions is by ordering a colonoscopy on a young patient who meets Rome IV criteria and has zero alarm features. The test-writer is evaluating whether you can make a positive clinical diagnosis without reflexively pursuing invasive workup. If the vignette describes a 28-year-old woman with chronic lower abdominal pain that improves after defecation, alternating stool consistency, bloating, normal labs, and no red flags, the answer is to diagnose IBS and begin dietary counseling, not to schedule a colonoscopy.

The second trap is confusing IBS with inflammatory bowel disease. The vignette will carefully omit bloody stool, weight loss, nocturnal symptoms, and elevated inflammatory markers if it wants you to pick IBS. Read the stem for what is absent, not just what is present. Normal fecal calprotectin is often the planted clue to steer you away from IBD.

A third trap involves missing celiac disease hidden as IBS-D. Always check celiac serologies in diarrhea-predominant presentations. If the vignette mentions iron deficiency, dermatitis herpetiformis, or a family history of autoimmune conditions, think celiac before IBS.

For treatment questions, know the subtype-to-drug pairing cold. Linaclotide is the go-to for IBS-C refractory to fiber. Rifaximin is the go-to for IBS-D with prominent bloating. Alosetron is reserved for severe IBS-D in women only and comes with the ischemic colitis warning. Eluxadoline is contraindicated in patients who have had a cholecystectomy because it increases the risk of sphincter of Oddi spasm and pancreatitis; this is a favorite test question.

Finally, remember that loperamide does not treat the pain component of IBS-D. If the question asks about persistent abdominal pain in a patient already on loperamide, the next step is adding a TCA or antispasmodic, not increasing the loperamide dose.

The core competency being tested is your ability to recognize a functional disorder by its positive diagnostic criteria, resist the urge to over-investigate when no alarm features are present, and match the correct pharmacologic agent to the correct IBS subtype.